AbbVie announced positive Phase 3 INTREPID study results for lutikizumab, a dual IL-1α/1β antagonist, in treating moderate to severe hidradenitis suppurativa (HS). The study met its primary endpoint with 31.4% of patients achieving HiSCR75 at Week 16 versus 23.4% for placebo, indicating significant reduction in skin lesions. Lutikizumab also improved HS-related skin pain and reduced disease flares, with a safety profile similar to placebo. These results support further development and regulatory submissions, with additional data expected in 2027.
AbbVie shares trade at USD 277.45 on Pluang as of Oct 22, 2026 20:11 WIB, down 2.55% for the day. The stock's market cap stands at $510.84 billion with a dividend yield of 2.39%. Despite the recent trial news, 63% of Pluang users are selling ABBV shares while 37% are buying.
Johnson & Johnson reported strong pharmaceutical growth with Innovative Medicine up 7.9%, driving optimism for its stock with a 12-month price target of $288.66, an 11.48% upside. However, its MedTech segment showed weak international sales growth an...
Retirees are increasingly turning to high-yield dividend stocks from diverse industries to supplement income beyond Social Security's fixed cost-of-living adjustments. Stocks like Verizon, Altria, AbbVie, Realty Income, and Enbridge offer yields from...
AbbVie has partnered with McLaren Racing as an Official Pharmaceutical Partner, launching the Race to Innovate campaign at the 2026 U.S. Grand Prix. For every 10 Constructors' Championship points McLaren earns, AbbVie will donate $10,000 to global ch...
In a Phase 2a study, ABBV-466, a dual-targeting therapy by AbbVie, achieved significantly higher endoscopic remission rates in Crohn's disease patients at Week 12 compared to anti-IL-23 p19 or anti-α4β7 monotherapies. The remission advantage increase...
At the 2026 European Society for Medical Oncology (ESMO) Congress, AbbVie presented new and updated data on its oncology portfolio, including investigational drugs like Temab-A, ABBV-706, and ABBV-969. These drugs showed encouraging clinical activity...
